市場調查報告書

慢性脫髓鞘多發性神經炎(CIDP) - 流行病學預測 2030年

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 524470
出版日期 內容資訊 英文 97 Pages
商品交期: 最快1-2個工作天內
價格
慢性脫髓鞘多發性神經炎(CIDP) - 流行病學預測 2030年 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Epidemiology Forecast - 2030
出版日期: 2020年03月01日內容資訊: 英文 97 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的慢性脫髓鞘多發性神經炎(CIDP)2017年的患病數估算為4萬4,700人。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙)的慢性脫髓鞘多發性神經炎(CIDP)市場調查,市場及疾病概要,整體及各國流行病學的預測,性別、各臨床類型、年齡的患病數及診斷數的變化與預測等相關資訊彙整。

目錄

第1章 重要的洞察

第2章 摘要整理

第3章 方法論

第4章 慢性脫髓鞘多發性神經炎(CIDP):患者概要

  • 患者的分佈(實在數值)
  • 患者的分佈(預測值)

第5章 慢性脫髓鞘多發性神經炎(CIDP):疾病背景和概要

  • 簡介
  • 分類
  • 臨床表現
  • CIDP與Guillain-barré症候群比較
  • CIDP與疾病的相關
  • CIDP的病因
  • 診斷
    • 診斷標準
    • 鑑別診斷
    • AAN電力診斷標準
    • Koski et al的標準
    • 歐洲神經學會及末梢神經學會的標準

第6章 相關組織

第7章 流行病學和患者數

  • 主要調查結果

第8章 主要7個國家的慢性脫髓鞘多發性神經炎(CIDP)的總患病數

第9章 美國

  • 假設和根據
  • 總患病數
  • 患病數:性別
  • 診斷數:各臨床類型
  • 患病數:各年齡

第10章 及歐洲5個國家日本

  • 德國
    • 假設和根據
    • 總患病數
    • 患病數:性別
    • 診斷數:各臨床類型
    • 患病數:各年齡
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第11章 關鍵意見領袖的意見

第12章 附錄

  • 報告方法

第13章 DelveInsight的服務內容

第14章 免責聲明

第15章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0055

DelveInsight's 'Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the CIDP, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Disease Understanding

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder. It is an acquired peripheral neuropathy due to an autoimmune attack of peripheral nerve myelin. Myelin is the main target of the condition, in which patients present with weakness, numbness, and sensory ataxia (symptoms of large myelinated fiber dysfunction). A great deal of evidence, such as the finding of inflammation at the site of the lesion, response to immunomodulatory treatment and possibly the presence of autoantibodies against myelin antigens. The inflammation of the peripheral nervous system damages the myelin sheaths that insulate nerve fibers. CIDP usually spares the nerves that supply muscles of respiration and the autonomic nerves that control the bladder, bowel, and circulation. The disorder sometimes also called chronic relapsing polyneuropathy.

The disease often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. It can occur at any age and in both genders, CIDP is more common in young adults, and men more so than women. This condition is treatable for relatively long periods (months to years) in the majority of patients. CIDP usually presents in the "classical" form as the symmetrical disorder with proximal and distal weakness but also can manifest as a variety of other subtypes that can be multifocal or selectively involve sensory or motor nerve fibers.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology

The CIDP epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total diagnosed prevalent cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients in 7MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted CIDP symptoms epidemiology segmented as the Total prevalence of CIDP, Gender-Specific cases of CIDP, Clinical Subtype cases of CIDP, Age-Specific cases of CIDP. The report includes the prevalent scenario of CIDP symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology

The epidemiology segment also provides the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of CIDP Associated in 7MM countries ranges from 44,700 in 2017.

  • As per the estimates, the United States has the highest prevalent population of CIDP.
  • Among the EU5 countries, France had the highest prevalent population of CIDP, followed by Germany. On the other hand, Spain had the lowest prevalent population with 1,727 cases in 2017.

Scope of the Report

  • The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Report and Model provide an overview of the risk factors and global trends of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of CIDP
  • The report provides the segmentation of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology by Prevalent Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM.
  • The report provides the segmentation of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology by gender-specific Prevalent Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM.
  • The report provides the segmentation of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology by age-specific Prevalent Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM.
  • The report provides the segmentation of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology by clinical subtype based diagnosed Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM

Report Highlights

  • 11-Year Forecast of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Prevalent Cases according to segmentation: Age-specific Prevalence of CIDP
  • Prevalent Cases according to segmentation: Gender-specific Prevalence of CIDP
  • Prevalent Cases according to segmentation: Clinical- subtype-specific Prevalence of CIDP
  • Diagnosed cases of CIDP

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CIDP?
  • What are the key findings pertaining to the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the CIDP?
  • What are the currently available treatments of CIDP?

Reasons to buy

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
  • Quantify patient populations in the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics in each of the markets covered
  • Understand the magnitude of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) population by its Prevalence cases
  • Understand the magnitude of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) population by its Gender-specific cases
  • Understand the magnitude of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) population by its Age-specific cases
  • Understand the magnitude of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) population by its Clinical subtype-specific cases
  • The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

According to the American Medical Association 2015, the prevalence rate of CIDP was 8.9 per 100,000 in the United States based on AAN criteria. According to the American Association of Neuromuscular & Electrodiagnostic Medicine, the occurrence of CIDP each year is estimated to be between 1.5 and 3.6 million in the population.

The GBS/CDP Foundation International and some authors suggest that CIDP affects men twice as often as women. Though more people develop CIDP when they are between the ages of 50 and 60 more than at any other time; however, people of all ages can get this disorder, from children to the elderly. The older patients may present with a more chronic, insidiously progressive motor and sensory polyneuropathy.

According to AHSAAN criteria, cases were classified as definite CIDP, probable CIDP, and possible CIDP.

Table of Contents

1. Key Insights

2. Executive summary

3. Methodology

4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Patient Overview at a Glance

  • 4.1. Total Patient Share (%) Distribution of CIDP in 2017
  • 4.2. Total Patient Share (%) Distribution of CIDP in 2030

5. Chronic inflammatory demyelinating polyneuropathy (CIDP): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Classification
  • 5.3. Clinical Presentation
  • 5.4. CIDP versus Guillain-Barre Syndrome
    • 5.4.1. Disease course
  • 5.5. Disease associations with CIDP
  • 5.6. Pathogenesis of CIDP
    • 5.6.1. FcRN role in the CIDP
  • 5.7. Diagnosis
    • 5.7.1. Diagnostic criteria
    • 5.7.2. Differential diagnosis
    • 5.7.3. AAN electrodiagnostic criteria
    • 5.7.4. Koski et al's criteria
    • 5.7.5. European Federation of Neurological Societies and the Peripheral Nerve Society

6. Organizations

7. Epidemiology and Patient Population

  • 7.1. Key Findings

8. Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM

9. United States Epidemiology

  • 9.1. Assumptions and Rationale
  • 9.2. Total Prevalent Population of CIDP in the United States
  • 9.3. Gender-Specific Prevalent Population of CIDP in the United States
  • 9.4. Clinical Subtype based Diagnosed cases of CIDP in the United States
  • 9.5. Age-Specific Prevalent Population of CIDP in the United States

10. EU5 Epidemiology

  • 10.1. Germany Epidemiology
    • 10.1.1. Assumptions and Rationale
    • 10.1.2. Total Prevalent Population of CIDP in Germany
    • 10.1.3. Gender-Specific Prevalent Population of CIDP in Germany
    • 10.1.4. Clinical Subtype based on Diagnosed cases of CIDP in Germany
    • 10.1.5. Age-Specific Prevalent Population of CIDP in Germany
  • 10.2. France Epidemiology
    • 10.2.1. Assumptions and rationale
    • 10.2.2. Total Prevalent Population of CIDP in France
    • 10.2.3. Gender-Specific Prevalent Population of CIDP in France
    • 10.2.4. Clinical Subtype based on Diagnosed cases of CIDP in France
    • 10.2.5. Age-Specific Prevalent Population of CIDP in France
  • 10.3. Italy Epidemiology
    • 10.3.1. Assumptions and Rationale
    • 10.3.2. Total Prevalent Population of CIDP in Italy
    • 10.3.3. Gender-Specific Prevalent Population of CIDP in Italy
    • 10.3.4. Clinical Subtype based on Diagnosed cases of CIDP in Italy
    • 10.3.5. Age-Specific Prevalent Population of CIDP in Italy
  • 10.4. Spain Epidemiology
    • 10.4.1. Assumptions and Rationale
    • 10.4.2. Total Prevalent Population of CIDP in Spain
    • 10.4.3. Gender-Specific Prevalent Population of CIDP in Spain
    • 10.4.4. Clinical Subtype based on Diagnosed cases of CIDP in Spain
    • 10.4.5. Age-Specific Prevalent Population of CIDP in Spain
  • 10.5. United Kingdom Epidemiology
    • 10.5.1. Assumptions and Rationale
    • 10.5.2. Total Prevalent Population of CIDP in the UK
    • 10.5.3. Gender-Specific Prevalent Population of CIDP in the UK
    • 10.5.4. Clinical Subtype based Diagnosed cases of CIDP in the UK
    • 10.5.5. Age-Specific Prevalent Population of CIDP in the UK
  • 10.6. Japan Epidemiology
    • 10.6.1. Assumptions and Rationale
    • 10.6.2. Total Prevalent Population of CIDP in Japan
    • 10.6.3. Gender-Specific Prevalent Population of CIDP in Japan
    • 10.6.4. Clinical Subtype based on Diagnosed cases of CIDP in Japan
    • 10.6.5. Age-Specific Prevalent Population of CIDP in Japan

11. KOL Views

12. Appendix

  • 12.1. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

List of Tables

  • Table 1: Major phenotypic variants of CIDP
  • Table 2: Clinical subtypes of chronic inflammatory demyelinating polyneuropathy
  • Table 3: Comparison of CIDP and subtypes
  • Table 4: Contrast of CIDP and Guillain Barre Syndrome
  • Table 5: Differential Diagnosis
  • Table 6: American Academy of Neurology Ad Hoc Subcommittee - electrodiagnostic criteria
  • Table 7: Koski et al's criteria for chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Table 8: Investigations to be considered
  • Table 9: EFNS/PNS Diagnostic Criteria for CIDP
  • Table 10: Total Prevalent Population of CIDP in the 7MM (2017-2030)
  • Table 11: Total Prevalent Population of CIDP in the US (2017-2030)
  • Table 12: Gender-Specific Prevalence of CIDP in the US (2017-2030)
  • Table 13: Clinical Subtype based Diagnosed cases of CIDP in the US (2017-2030)
  • Table 14: Age-Specific Prevalence of CIDP in the US (2017-2030)
  • Table 15: Total Prevalent Population of CIDP in Germany (2017-2030)
  • Table 16: Gender-Specific Prevalence of CIDP in Germany (2017-2030)
  • Table 17: Clinical Subtype based Diagnosed cases of CIDP in Germany (2017-2030)
  • Table 18: Age-Specific Prevalence of CIDP in Germany (2017-2030)
  • Table 19: Total Prevalent Population of CIDP in France (2017-2030)
  • Table 20: Gender-Specific Prevalence of CIDP in France (2017-2030)
  • Table 21: Clinical Subtype based Diagnosed cases of CIDP in France (2017-2030)
  • Table 22: Age-Specific Prevalence of CIDP in France(2017-2030)
  • Table 23: Total Prevalent Population of CIDP in Italy (2017-2030)
  • Table 24: Gender-Specific Prevalence of CIDP in Italy (2017-2030)
  • Table 25: Clinical Subtype based Diagnosed cases of CIDP in Italy (2017-2030)
  • Table 26: Age-Specific Prevalence of CIDP in Italy (2017-2030)
  • Table 27: Total Prevalent Population of CIDP in Spain (2017-2030)
  • Table 28: Gender-Specific Prevalence of CIDP in Spain (2017-2030)
  • Table 29: Clinical Subtype based Diagnosed cases of CIDP in Spain (2017-2030)
  • Table 30: Age-Specific Prevalence of CIDP in Spain (2017-2030)
  • Table 31: Total Prevalent Population of CIDP in the UK (2017-2030)
  • Table 32: Gender-Specific Prevalence of CIDP in the UK (2017-2030)
  • Table 33: Clinical Subtype based Diagnosed cases of CIDP in the UK (2017-2030)
  • Table 34: Age-Specific Prevalence of CIDP in the UK (2017-2030)
  • Table 35: Total Prevalent Population of CIDP in Japan (2017-2030)
  • Table 36: Gender-Specific Prevalence of CIDP in Japan (2017-2030)
  • Table 37: Clinical Subtype based Diagnosed cases of CIDP in Japan (2017-2030)
  • Table 38: Age-Specific Prevalence of CIDP in Japan (2017-2030)

List of Figures

  • Figure 1: Schematic presentation of the distribution of demyelinating lesions
  • Figure 2: Immunopathogenesis of Chronic Inflammatory Demyelinating Neuropathy
  • Figure 3: Immunopathogenesis of Chronic Inflammatory Demyelinating Neuropathy
  • Figure 4: Algorithm of Diagnostic procedures
  • Figure 5: Total Prevalent Population of CIDP in the 7MM (2017-2030)
  • Figure 6: Total Prevalent Population of CIDP in the US (2017-2030)
  • Figure 7: Gender-Specific Prevalence of CIDP in the US (2017-2030)
  • Figure 8: Clinical Subtype based Diagnosed cases of CIDP in the United States (2017-2030)
  • Figure 9: Age-Specific Prevalence of CIDP in the US (2017-2030)
  • Figure 10: Total Prevalent Population of CIDP in Germany (2017-2030)
  • Figure 11: Gender-Specific Prevalence of CIDP in Germany (2017-2030)
  • Figure 12: Clinical Subtype based Diagnosed cases of CIDP in Germany (2017-2030)
  • Figure 13: Age-Specific Prevalence of CIDP in Germany (2017-2030)
  • Figure 14: Total Prevalent Population of CIDP in France (2017-2030)
  • Figure 15: Gender-Specific Prevalence of CIDP in France (2017-2030)
  • Figure 16: Clinical Subtype based Diagnosed cases of CIDP in France (2017-2030)
  • Figure 17: Age-Specific Prevalence of CIDP in France (2017-2030)
  • Figure 18: Total Prevalent Population of CIDP in Italy (2017-2030)
  • Figure 19: Gender-Specific Prevalence of CIDP in Italy (2017-2030)
  • Figure 20: Clinical Subtype based Diagnosed cases of CIDP in Italy (2017-2030)
  • Figure 21: Age-Specific Prevalence of CIDP in Italy (2017-2030)
  • Figure 22: Total Prevalent Population of CIDP in Spain (2017-2030)
  • Figure 23: Gender-Specific Prevalence of CIDP in Spain (2017-2030)
  • Figure 24: Clinical Subtype based Diagnosed cases of CIDP in Spain (2017-2030)
  • Figure 25: Age-Specific Prevalence of CIDP in Spain (2017-2030)
  • Figure 26: Total Prevalent Population of CIDP in the UK (2017-2030)
  • Figure 27: Gender-Specific Prevalence of CIDP in the UK (2017-2030)
  • Figure 28: Clinical Subtype based Diagnosed cases of CIDP in the UK (2017-2030)
  • Figure 29: Age-Specific Prevalence of CIDP in the UK (2017-2030)
  • Figure 30: Total Prevalent Population of CIDP in Japan (2017-2030)
  • Figure 31: Gender-Specific Prevalence of CIDP in Japan (2017-2030)
  • Figure 32: Clinical Subtype based Diagnosed cases of CIDP in Japan (2017-2030)
  • Figure 33: Age-Specific Prevalence of CIDP in Japan (2017-2030)